Canine Atopic Dermatitis Treatment Market

2019 Analysis and Review of Canine Atopic Dermatitis Treatment Market by Drug Class - Corticosteroids, Immunosuppressants, Antibiotics, Antihistamines, Emollients, Essential Fatty Acids, Antipruritics, and Monoclonal Antibodies for 2019-2029

Monoclonal Antibodies to Emerge as Pervasive Drug Class

At present, immunosuppressant drugs account for a pronounced share in the global canine atopic dermatitis treatment market. However, growing resistance to various therapeutic chemical agents are limiting their effectiveness, and, as such, their market share will partially stagnate in the coming years.

Going forward, monoclonal antibodies (mAb) would emerge as a preferable drug class, owing to their high biological specificity in targeting canine atopic dermatitis. Although a newly developed drug class, mAbs will surpass immunosuppressant drugs in terms of value share during the latter half of the forecast period.

North America Market to Enter Billion-dollar Club in 2029

North America, on the back of rising pet ownership and strong presence of technology-forward healthcare infrastructure, continues to stay in the vanguard of the canine atopic dermatitis treatment market. Moreover, the developed regional market is likely to hit US$ 1 Bn mark by the end of 2029.

Growing demand for animal healthcare services in Europe to improve food safety systems and veterinary public health in order to safeguard human health is also reflecting investment opportunities. For instance, Companion Insurance has been implemented to promote the efficiency of animal healthcare systems.

Flexible Ecosystem of Collaborations - Imperative for Bigger Gains

Canine atopic dermatitis treatment market players are focusing on entering into strategic collaborations for manufacturing veterinary vaccines. Boragen Inc., for instance, has inked an agreement with a leading animal health company for the discovery and development of canine atopic dermatitis treatment.

This collaboration would aid the healthcare firm in producing advanced compounds targeting canine atopic dermatitis. Moreover, Immunomic Therapeutics Inc. has offered ZENOAQ an exclusive license to develop and commercialize its investigational DNA vaccine - ITI-002, for canine atopic dermatitis treatment.

How Growth will Unfold

Oral administration of veterinary medicine is currently the preferred route for drug delivery to treat canine atopic dermatitis, leading with around half of total market revenue. However, towards the end of the projection period, it will lose its prominent status to injectable drug delivery in the canine atopic dermatitis treatment market. Witnessing triple-digit growth in its adoption in 2018, injectable administration of veterinary drugs is gaining rapid prominence, owing to lesser side effects and fast-paced recovery.


What are the factors contributing to the growth of the canine atopic dermatitis treatment market?

Increasing incidence of canine atopic dermatitis and growing adoption of pets in emerging countries such as China and India have resulted in propelling the demand for animal therapeutics, which has benefited the growth of the canine atopic dermatitis treatment market.

How are gaps in epidemiological knowledge hampering canine atopic dermatitis treatment market growth?

There exists a large gap in understanding the epidemiology pattern of veterinary diseases such as canine atopic dermatitis, due to variations in the disease pattern in certain endemic countries. This limits the development of multiple canine atopic dermatitis genotypes, hampering the discovery and production of novel vaccines.

What are the leading trends among end users contributing to the growth of the canine atopic dermatitis treatment market?

Drug manufacturers in the canine atopic dermatitis treatment market are taking comprehensive efforts to establish direct customer relations in order to understand unmet needs to develop new treatments for canine atopic dermatitis.

Which type of treatment has noteworthy growth potential during the forecast period??

Monoclonal antibodies are expected to witness relatively high demand, owing to significant biological efficacy in targeting canine atopic dermatitis.

Which region will offer lucrative opportunities for canine atopic dermatitis treatment market players?

East Asia is expected to show significant growth opportunities during the forecast period, owing to noteworthy industrial and infrastructural growth of bio-pharmaceutical companies in China and South Korea. Japan and China will remain the top two target geographies for drug manufacturers to expand their regional presence.

Who are the leading players in the canine atopic dermatitis treatment market?

The market is dominated by three major players - Elanco Animal Health, Merck KGaA, and Johnson & Johnson Services, Inc. These tier 1 players collectively hold 2/3 revenue share of the global canine atopic dermatitis treatment market.


The global canine atopic dermatitis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug Class

  • Corticosteroids
  • Immunosuppressants
  • Antibiotics
  • Antihistamines
  • Emollients
  • Essential Fatty Acids
  • Antipruritics
  • Monoclonal Antibodies

Mode of Administration

  • Topical
  • Oral
  • Injectable

Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies


  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports


Canine Atopic Dermatitis Treatment Market